Darifenacin Tablet, Extended Release
Product Images NDC 62332-224

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 62332-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Darifenacin 15 mg

Darifenacin Extended-Release Tablets 15 mg, oral extended-release tablets packaged in a carton containing 30 tablets. The label includes dosage instructions, storage conditions, manufacturer details Alembic Pharmaceuticals Limited in India, and Alembic Pharmaceuticals Inc. in the USA, along with a barcode and NDC 62332-224-30.*

FDA Label Image

Darifenacin 2a

A line graph showing median reduction over 12 weeks in the number of incontinence episodes per week from baseline. It compares three groups: placebo (dotted line with open circles), Darifenacin 7.5 mg (solid line with filled squares), and an unidentified third group (solid line with filled triangles). The y-axis represents reduction in episodes, and the x-axis represents time in weeks.*

FDA Label Image

Darifenacin 2b

A line graph showing the median reduction in incontinence episodes per week from baseline over 12 weeks. The graph compares placebo and two doses of Darifenacin (7.5 mg and 15 mg) extended-release tablets, illustrating greater reductions with both Darifenacin doses compared to placebo over time.*

FDA Label Image

Darifenacin 2c

A line graph depicting the median reduction in incontinence episodes per week from baseline over a 12-week period. The graph compares two groups: Placebo (dotted line with open circles) and Darifenacin 15 mg (solid line with filled squares). Error bars indicate the 95% confidence intervals at various time points (0, 2, 6, 12 weeks). The reduction is shown on the y-axis, with time in weeks on the x-axis.*

FDA Label Image

Darifenacin 7 5 mg

Label for Darifenacin Extended-Release Tablets 7.5 mg by Alembic Pharmaceuticals Inc. The label states each tablet contains 8.929 mg of darifenacin hydrobromide equivalent to 7.5 mg darifenacin. It is a 30-tablet bottle for oral use with instructions to store at 25°C with permitted excursions. The label includes manufacturer details from Alembic Pharmaceuticals Limited, Gujarat, India, and Alembic Pharmaceuticals Inc., New Jersey, USA.*

FDA Label Image

Figure 1 (Darifenacin Figure1)

A line graph showing Darifenacin plasma concentration (ng/mL) over 24 hours post-dose for 7.5 mg and 15 mg oral extended-release tablets. The graph depicts mean concentrations with standard deviation error bars, illustrating higher plasma levels for the 15 mg dose compared to 7.5 mg over time.*

FDA Label Image

Darifenacin Structure

Chemical structure of darifenacin, shown as a molecular diagram with labeled functional groups including a piperidine ring, amide, and functional groups attached to an indole-like bicyclic system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.